The Highwire with Del Bigtree - MORE EVIDENCE OF HARM FROM STATINS

Episode Date: December 19, 2023

MORE EVIDENCE OF HARM FROM STATINSBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

Anybody watching the show should know that with pharmaceutical companies and their products, it's kind of a trust to trust, but verify or don't trust and verify. But you want to do that first. And so let's talk about one of the biggest blockbuster drugs of all time. These are statins. These are cholesterol lowering medications. Everyone probably knows someone on them or has been on them themselves. And this, again, billions, hundreds of billions of dollars, these have generated pharmaceutical companies.

And one of the biggest ones was Pfizer's Lipitor. And Lipitor came out in 1997. It was just that it changed the whole game at that point. And so looking back, there's an article on this. It says about how it changed the game. It's titled, it took a brilliant marketing campaign to create the best-selling drug of all time. And it says here, Pfizer benefited from some lucky timing. Lipitor went on sale in 1997, the year the Food and Drug Administration first allowed drug ads targeting consumers.

So you started seeing those commercials. it says. So Pfizer spent tens of millions on ads, including on the popular drama, ER, first urging patients to know your numbers, and then showing patients discussing, discuss how Lipitor helped them get their cholesterol numbers below guideline goals. But listen to this. Meanwhile, health groups, now a lot of these health groups have been found out of huge conflicts of interest. Meanwhile, health groups kept lowering the cholesterol targets and national guidelines, making millions more patients good candidates for statin treatment. So it's devastatingly, evil the marketing because if you have a new like create a problem and then say you have the solution

to fix it oh well no just lower the cholesterol see your cholesterol's high you need us and people like millions of me i mean i think it's like almost half of this nation of adults are or are taking a statin and so the statins are lipitor for that matter for at-risk patients with a cholesterol number at you know whatever level at that time so the brilliant marketing if it wasn't so evil the brilliant marketing is instead of going back and testing, it takes hundreds of millions of dollars, if not billions, to bring these huge drugs like this to market and sustain them. So instead of going back and doing that, they just paid industry groups. They had these conflicts of interest to just lower that cholesterol number. And whoops, now we have a whole new group of people that are

going to take these drugs. And Lipitor became Pfizer's best-selling drug. It literally sustained the company for years, about 20 to 25 percent of its annual revenue. just give you an idea on that wow and it became the conversation around statins became so loose around the around that the time and during the 2000s that people were talking about putting it in the safety was just so safe no problem at all just like opioids and the rest of the stuff we've covered vaccines you know it's just natural these natural components lipidano particles you saw headlines like this would you like statins with that fast food outlets urge to hand out cholesterol lowering drugs and even this one USA today statins in the drinking water now that was just kind of a play on that

It was almost a joke, but it got the conversation going. And people really understood, like, wow, this is just such a safe drug. They're talking about maybe putting in the water. This is no big deal then. I'll obviously take this. Well, it's been known, obviously, with statins that there's people that take them, they get muscle pain, they get neuropathy, sometimes liver issues, sometimes vision issues. But in all the studies, it'll say, well, those risks are worth the benefits that this drug will give you. But now we've been continuing seeing new studies coming out over the last three, four years of some really bad side effects.

And the pharmaceutical companies are really silent on these. Here's one of them. Statin used to lower cholesterol linked to double risk of developing dementia. Patients, it says, with mild cognitive impairment or normal cognition who use lipophilic statins were found to have more than double the risk of developing dementia compared to statin non-users. Over time, PET imaging of lipophilic statin users also showed a substantial decline in metabolism in the posterior cingulate cortex, the region of the brain known to decline the most significantly in the earliest stages of Alzheimer's disease. So looking at this study, it's almost as if it's accelerating this.

And these are the lipophilic, these are the fat-loving statins. There's a couple different types, but these seem to be a pretty big question. Now, here's another study. Now, we get even further into these really, really nasty disease. Amelotrophic lateral sclerosis, this is ALS, a terribly bad wasting disease associated with statins, statin use, a disproportionality analysis of the FDA's adverse reporting system. So the CDC has the VERS, the vaccine adverse event reporting system, and FDA has its own. So when these drugs go to market, they have, you know, small trials that are usually done by the manufacturer. And as we've seen through COVID, they say, looks good to me, get it out to the public.

And then we'll see the real safety profile. So that's where these reporting systems, if they're working good, come in. And so the study says this. The aim of the study was to examine U.S. FDA adverse reporting system data to compare reporting odds ratios of ALS and ALS-like conditions between statins and other drugs for each statin agent. So simply what they did was they looked at, let's look at all the drugs people are taking and look at people taking statins. Is there a difference in ALS with statins?

And this is what they found. The reporting odds ratio for ALS were elevated for all statins, with elevations possibly stronger for lipophilic statins. Reporting odds ratios range from 9.09 to 16.2 times. Now, this isn't percent. This is times for resverastatin and pravastatin. These are hydrophilic. These are water-loving to 17, 23, and 160.

seven times for a trovastatin, simovastatin, and lovastatin. It was a lipophilic, respectively. For simovastatin, an ROR of 57.1 was separately present for motor neuron disease. So they found that too, over 57 times of regular, regular just medication people are taking. So let's pause right there for a second. Let's just take a look at ALS.

I'll bet you there are people in our audience right now that are saying, oh my God, I thought, It was okay, this was safe. You know, and when we look at these things, I just think even talk to Pierre Corey, you know, why is it that science just makes this assumption that there's gonna be no downstream effects? Like even, this is the problem with science.

It's looking through a microscope. Oh look, it reduces cholesterol, does exactly what wanted to do? But what does reducing cholesterol do to the rest of your body? And how many years would it take and how many people would have to be in that study for us to figure it out? On these numbers, not that many people would have to be in it.

If you're looking at nine, 10, 20 times, 50 times the amount, I mean, it's, it's, you know, it's clearly a super strong signal and really alarming. Absolutely. And so during the pandemic, a researcher came up with a medical hypothesis of ALS, and this is how it goes. This is the title of this paper, micro toxins causing amyotrophic lateral sclerosis. It says ALS remains a terminal disease without an established etiology for the majority of So they don't know, they really don't know. The dormant theory of ALS, I'm sorry, the dominant theory of ALS before the 1970s was the presence

of a poison. One of the primary means of treating patients with a toxic exposure has been plasma exchange, but plasma exchange of ALS patients failed to alter the clinical course. The failure of plasma exchange assumes the patient is no longer exposed to the poison. If the exposure to poison continued, then plasma exchange alone would fail. He goes on to say this. I found laboratory evidence of a poisoning in every patient with ALS examined. A search for specific poisons found evidence of mycotoxins.

Treatment with antifungal agents corrected the laboratory findings. All of the ALS patients had evidence of immune suppression. There's mounting evidence that many mycotoxins cause both neurotoxicity and immune suppression. These microtoxins may be able to explain the full spectrum of pathology in ALS without a secondary event. So that's pretty big deal right there. and there's a lot of people and researchers that are now starting to look at this route and starting to study this route.

But let's go back to statins for a second. What are statins? How are they found? Why would an antifungal work in this space? It begs that it asks a lot of questions. A lot of questions here. So let's introduce the fungal component, it's a mold component, penicillium, citronum.

And you can see here from this paper, you go into the title, targeting cholesterol synthesis therapeutically. It says, first isolated as a mold. Penicillium citronum statins have become one of the most prescribed medicines in the world. So this has been synthesized from a mold. It says in 1973, after a year of painstaking work assaying more than 3,800 fungal strains, Akira Endo's team discovered a potent HMGCR inhibitor, mevastatin, also called compactin.

Under the trademark Mevacore, the pharmaceutical company Merck developed a chemically related compound, Lova statin in 1987, which became the first statin to reach patients. Over subsequent years, a number of statins have become available, each tending to be more potent than their predecessors. With Lipitor being what was called a turbostatin, it was so potent that you didn't need that much of it at all. So here we have the- People are taking this every day, right?

Like you're just constantly subjecting your body to this, you know, mold derivative. Right. And how many people are taking this? Well, this is article just recently. It says 35% of eligible adults in the U.S. use them. We're talking 100 to millions around the world, but 35% of eligible adults. And so is there a benefit from these? So, I mean, we're back to the square run here.

We're finding out all of these, you know, you call them adverse events, these major harms, these, you know, life-ending harms in some cases. What's the benefit? Is it really worth it? Well, we go to Dr. Assim Mahaltra. He's somebody that people on our show may have just first heard of. and the vaccine conversation, but he has been sounding the alarm for statins because he is a cardiologist for several years. Listen to him, talk about the efficacy. The reality is when you break down the

data, even from industry-sponsored trials on statins, because most of this information comes from drug companies who sponsored trials, so it's likely an exaggeration, but even if we take that as gospel truth, if you are at, say, low risk of heart disease, you've not had a heart attack, then the chances of a statin benefiting you over a five-year period based upon the trials that showed those benefits on an individual level are about 1% one-and-a-hundred so what i would say to my patients if i'm having a conversation with them about statins for example is i would say listen if you take this drug religiously every day for the next five years there's a 1% chance it's going to prevent you having heart attack or stroke but it will not prolong your life by one day because that that

that isn't shown to be beneficial for mortality in low-risk people Wow. And I mean, this is where, again, you just see the pharmaceutical machine, the pawn doctors that are just pumping this stuff out. They're fed with these studies that is totally effective, does so much, and is perfectly safe, and how many people have been pumped full of this crap and have done nothing really except to just put their lives at risk and raise the potential of a very long, slow, ugly death. And as long as we're on air, we're going to expose every single one of these. I promise I promise you that. Every single one of these myths that have been sold through multi-million

dollar marketing like they did with Lipitor and OxyContin and all of these. We're going to expose every one of these. We'll show you the documents. We'll show you the discovery in court cases. If people are lucky enough to get these creatures into court and get discovery, we'll be doing this every week on this channel. It's amazing, Jeffrey. The way, you know, you and our team are piecing all these different bits together, it's not just a headline. the whole history, it's so important for us to understand this. Great work, Jeffrey, really great.